ArticleBlood cancer journal2023

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma.

Wee-Joo Chng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.